# US 2012/0083454 A1 · Eph receptor expression in tumor stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0083454 A1
- Document ID: US20120083454A1
- Status: Published application
- Kind: A1
- Application number: 13/089,217
- Filed: 2011-04-18
- Published: 2012-04-05
- Earliest claimed: 2010-10-01
- Assignees: Stemgen S.P.A.
- Inventors: Angelo Luigi Vescovi; Elena Binda
- Web page: https://patentgrep.com/patent/US20120083454A1

## CPC

- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure concerns the field of malignant tumors of the central nervous system and provides pharmaceutical compositions suitable for the therapeutic and for the prophylactic treatment of brain tumors and for inhibiting the growth of the tumor mass.

## Claims

### Claim 1

A method to treat a brain tumor in an individual, the method comprising administering to the individual an effective amount of an inhibitor of expression and/or activity of an Ephrin receptor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the tumor is glioblastoma.

### Claim 3 (depends on 1)

The method of claim 1, wherein the tumor is glioblastoma multiforme.

### Claim 4 (depends on 1)

The method of claim 1, wherein the treatment is a therapeutic treatment of brain tumor recurrence after surgery.

### Claim 5 (depends on 1)

The method of claim 1, wherein the treatment is a prophylactic treatment of brain tumor recurrence after surgery.

### Claim 6 (depends on 1)

The inhibitor of claim 1, wherein the effective amount is administered to inhibit the growth of a brain tumor mass.

### Claim 7 (depends on 1)

The method of claim 1, wherein the inhibitor is an inhibitor of cancer stem cell proliferation.

### Claim 8 (depends on 1)

The method of claim 1, wherein the inhibitor has a sequence selected from the group consisting of SEQ ID NO. 1 and SEQ ID NO. 3.

### Claim 9

A pharmaceutical composition comprising at least one inhibitor of expression and/or activity of an Ephrin receptor and a pharmaceutically acceptable bioactive agent.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, wherein the inhibitor is an inhibitor of cancer stem cell proliferation.

### Claim 11 (depends on 9)

The pharmaceutical composition of claim 9, wherein the inhibitor is an inhibitor of cancer stem cell migration.

### Claim 12 (depends on 10)

The pharmaceutical composition of claim 10, wherein said cancer stem cell is a malignant brain cancer stem cell.

### Claim 13 (depends on 9)

The pharmaceutical composition of claim 9, wherein the inhibitor has a sequence is selected form the group consisting of SEQ ID NO. 1 and SEQ ID NO. 3.
